New Age Alpha Advisors LLC Acquires Shares of 7,082 TG Therapeutics, Inc. (NASDAQ:TGTX)

New Age Alpha Advisors LLC bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX) during the fourth quarter, Holdings Channel.com reports. The firm bought 7,082 shares of the biopharmaceutical company’s stock, valued at approximately $213,000.

Other institutional investors also recently modified their holdings of the company. Bleakley Financial Group LLC bought a new stake in TG Therapeutics during the fourth quarter worth $245,000. Castellan Group purchased a new stake in shares of TG Therapeutics during the 4th quarter valued at $8,539,000. Barclays PLC raised its stake in shares of TG Therapeutics by 83.9% during the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock worth $8,117,000 after purchasing an additional 158,323 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of TG Therapeutics by 60.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock worth $16,859,000 after buying an additional 270,286 shares during the last quarter. Finally, Neo Ivy Capital Management bought a new position in TG Therapeutics during the third quarter valued at about $2,358,000. 58.58% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Price Performance

TGTX opened at $39.82 on Thursday. The firm has a 50-day moving average price of $34.94 and a 200-day moving average price of $30.67. TG Therapeutics, Inc. has a twelve month low of $12.93 and a twelve month high of $43.32. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The company has a market capitalization of $6.25 billion, a price-to-earnings ratio of -398.16 and a beta of 2.13.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.07. The business had revenue of $108.19 million during the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. Equities analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Insider Activity at TG Therapeutics

In related news, CFO Sean A. Power sold 11,337 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $30.29, for a total transaction of $343,397.73. Following the sale, the chief financial officer now owns 670,632 shares of the company’s stock, valued at approximately $20,313,443.28. This represents a 1.66 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 10.50% of the stock is currently owned by corporate insiders.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.